We have collected information about Intracellular Delivery Considerations For Rnai Therapeutics for you. Follow the links to find out details on Intracellular Delivery Considerations For Rnai Therapeutics.
https://www.researchgate.net/publication/278691994_Intracellular_Delivery_Considerations_for_RNAi_Therapeutics
Request PDF Intracellular Delivery Considerations for RNAi Therapeutics Intracellular delivery of the wide range of RNAi therapeutics is a complex process that remains to be fully understood ...
https://link.springer.com/chapter/10.1007/978-1-4614-4744-3_4
Sep 14, 2012 · Intracellular delivery of the wide range of RNAi therapeutics is a complex process that remains to be fully understood and mastered. This chapter discusses the current understanding of the process of intracellular delivery of RNAi triggers from multiple perspectives.Author: Yu Zhu, Jing Li, David Oupický
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2977003/
Jun 11, 2010 · Comparisons of RNAi Therapeutics. ... Cationic cell penetrating peptides (CPP) have been used for the intracellular delivery of macromolecules including proteins (e.g., antibodies), ... Evaluation of the efficacy of siRNA therapeutics requires considerations of off-target effects and innate immune response.Author: Jie Wang, Ze Lu, M. Guillaume Wientjes, Jessie L.-S. Au
https://www.sciencedirect.com/science/article/pii/S1525001616319864
Introduction. The key to enabling therapeutics based on RNA interference (RNAi) is the safe and efficacious delivery of short interfering RNAs (siRNAs), the mediators of RNAi, to the appropriate tissues, cells, and ultimately, intracellular compartments where the natural RNAi machinery may be engaged for target mRNA silencing resulting in protein knockdown.Author: Martin A Maier, Muthusamy Jayaraman, Shigeo Matsuda, Ju Liu, Scott Barros, William Querbes, Ying K T...
https://www.sciencedirect.com/science/article/pii/S0168365915302832
Materials for non-viral intracellular delivery of messenger RNA therapeutics. ... the inherent immune-activating adjuvant properties of foreign RNAs can be leveraged for the intracellular delivery of mRNAs coding for specific ... et al.Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol. Ther., 18 ...Author: Kevin J. Kauffman, Matthew J. Webber, Matthew J. Webber, Daniel G. Anderson
https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-017-0450-0
Jun 27, 2017 · In this review, we discuss the challenges for clinical translation of RNA-based therapeutics, with an emphasis on recent advances in delivery technologies, and present an overview of the applications of RNA-based drugs for modulation of gene/protein expression and genome editing that are currently being investigated both in the laboratory as ...Author: James C. Kaczmarek, Piotr S. Kowalski, Daniel G. Anderson
https://www.nature.com/articles/s41467-018-03705-y
Apr 12, 2018 · Cellular barriers to successful intracellular delivery of the encapsulated therapeutics and complex design are some additional factors specific to the actively targeted NCs that limit their ...Author: Daniel Rosenblum, Nitin Joshi, Nitin Joshi, Wei Tao, Jeffrey M. Karp, Jeffrey M. Karp, Dan Peer
https://www.ddw-online.com/therapeutics/p322575-current-trends-in-rna-therapeutics-development.html
New in vivo RNA delivery technologies including LNP or PNP systems and the use of aptamer or antibody conjugation have overcome some of the challenges associated with delivery of RNA-based therapeutics, with the selection of the delivery system depending on the therapeutics properties, type of target cell and desired delivery route.
https://www.researchgate.net/publication/26281205_Intracellular_delivery_of_siRNA_by_cell-penetrating_peptides_modified_with_cationic_oligopeptides
The delivery requirements are primarily determined by the properties and intracellular site of action of the RNAi molecule. Main intracellular barriers to nonviral delivery of siRNA, shRNA, and ...
https://rnaitherapeutics.blogspot.com/2013/
Dec 24, 2013 · Whereas RNAi Therapeutics have more or less conquered the liver, opening up a whole host of indications to RNAi Therapeutics, despite the apparent accessibility of the vascular endothelial system to delivery and promising animal studies, it has proven a more difficult tissue to firmly establish gene-specific knockdowns.
Searching for Intracellular Delivery Considerations For Rnai Therapeutics?
You can just click the links above. The data is collected for you.
